Trials / Completed
CompletedNCT00306878
Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (planned)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical research study is to determine the safety, pharmacokinetics, immunogenicity in humans, the recovery time required from the biologic effects and the optimal biologic dose range of BMS188667 (CTLA4Ig)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abatacept |
Timeline
- Start date
- 1995-08-01
- Primary completion
- 1997-05-01
- Completion
- 1997-05-01
- First posted
- 2006-03-27
- Last updated
- 2011-04-13
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00306878. Inclusion in this directory is not an endorsement.